AQW-051
 | |
| Clinical data | |
|---|---|
| Other names | AQW051, VQW-765 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H22N2O |
| Molar mass | 294.398 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AQW-051 also known as VQW-765 is an orally available, highly selective partial agonist of the alpha-7 nicotinic receptor (nAChR)[1][2] developed by Novartis as a central nervous system agent aimed at improving cognitive function in disorders such as schizophrenia and Alzheimer's disease, and for reducing L-Dopa–induced dyskinesias in Parkinson's disease.[1] AQW-051 had reached Phase 2 clinical trials for conditions like schizophrenia and Parkinson’s disease, but development for Alzheimer’s disease has been discontinued.[3][4]
It was later licensed it to Vanda Pharmaceuticals and who are evaluating it in phase 3 clinical trials for phobic disorders[5] and social anxiety.[6]
References
[edit]- ^ a b Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B (November 2014). "AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys". Parkinsonism & Related Disorders. 20 (11): 1119–1123. doi:10.1016/j.parkreldis.2014.05.007. PMID 25172125.
- ^ Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, et al. (March 2015). "AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation". British Journal of Pharmacology. 172 (5): 1292–304. doi:10.1111/bph.13001. PMC 4337702. PMID 25363835.
- ^ Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, et al. (November 2016). "Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial". Progress in Neuro-psychopharmacology & Biological Psychiatry. 71: 66–75. doi:10.1016/j.pnpbp.2016.06.013. PMC 6432789. PMID 27371157.
- ^ Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, et al. (July 2016). "A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia". Movement Disorders : Official Journal of the Movement Disorder Society. 31 (7): 1049–54. doi:10.1002/mds.26569. PMID 26990766.
- ^ "VQW-765". AdisInsight. Springer Nature Switzerland AG.
- ^ He Y, Polymeropoulos CM, Mohrman MA, Truslow SO, Xiao C, Wu Y, et al. (July 2025). "Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial". The British Journal of Psychiatry : The Journal of Mental Science. 227 (1): 473–480. doi:10.1192/bjp.2025.84. PMC 12278049. PMID 40340771.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |